BGB-11417-204: Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Sponsor: BeOne Medicines
Full Title
BGB-11417-204: A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With
Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia
Study Treatment
Zanubrutinib +/- Sonrotoclax
BGB-11417 (sonrotoclax) is a highly potent and selective Bcl-2 protein inhibitor.
Zanubrutinib is a more selective covalent BTK inhibitor.
Eligibility/Info
Untreated chronic lymphocytic leukemia that requires first line systemic therapy.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
